Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Non-Current Receivables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Non-Current Receivables for 7 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Receivables rose 3.51% to $7.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.4 million, a 3.51% increase, with the full-year FY2025 number at $7.4 million, up 3.51% from a year prior.
  • Non-Current Receivables was $7.4 million for Q4 2025 at ImmunityBio, up from $7.3 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $7.4 million in Q4 2025 to a low of $810000.0 in Q1 2021.
  • A 5-year average of $6.5 million and a median of $6.8 million in 2023 define the central range for Non-Current Receivables.
  • Biggest YoY gain for Non-Current Receivables was 695.19% in 2022; the steepest drop was 3.12% in 2022.
  • ImmunityBio's Non-Current Receivables stood at $6.4 million in 2021, then increased by 3.12% to $6.6 million in 2022, then increased by 4.23% to $6.9 million in 2023, then increased by 3.65% to $7.1 million in 2024, then grew by 3.51% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non-Current Receivables are $7.4 million (Q4 2025), $7.3 million (Q3 2025), and $7.3 million (Q2 2025).